Cargando…

Effect of 48-week pegylated interferon α-2a or nucleos(t)ide analogue therapy on renal function in Chinese patients with chronic hepatitis B

BACKGROUND: Controversy remains as to whether antiviral agents contribute to renal dysfunction in patients with chronic hepatitis B virus (HBV) infection. Thus, the aim of study was to analyze the changes in renal function of chronic hepatitis B (CHB) patients in response to anti-HBV therapy and the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Ye, Zhang, Wei-Lu, Pang, Xiao-Wen, Wang, Lin-Xu, Wei, Xin, Huang, Chang-Xing, Bai, Xue-Fan, Han, Shuai, Liu, Lin-Na, Lian, Jian-Qi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5343434/ https://www.ncbi.nlm.nih.gov/pubmed/28274240 http://dx.doi.org/10.1186/s12985-017-0712-x

Ejemplares similares

Potential Efficacy of Pegylated Interferon-α and a Nucleos(t)ide Analogue as Combination Therapy for HBeAg-Positive Chronic Hepatitis B
por: Wi, Chung-Il, et al.
Publicado: (2016)

Serum IL-5 levels predict HBsAg seroclearance in patients treated with Nucleos(t)ide analogues combined with pegylated interferon
por: Wang, Peipei, et al.
Publicado: (2023)

48-Week Outcome after Cessation of Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Patient and the Associated Factors with Relapse
por: Xu, Wen-xiong, et al.
Publicado: (2018)

Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide analogue-naïve and nucleos(t)ide analogue-experienced chronic hepatitis B patients
por: Jung, Sang Kyung, et al.
Publicado: (2015)

Comment on “48-Week Outcome after Cessation of Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Patient and the Associated Factors with Relapse”
por: Guo, Yafei, et al.
Publicado: (2019)

Combination of Pegylated Interferon and Nucleos(t)ide Therapy: Toward a Cure of Hepatitis B Virus Infection?
por: Cho, Eun Ju, et al.
Publicado: (2016)

Durability of Nucleos(t)ide Analogues Treatment in Patients With Chronic Hepatitis B
por: Lee, I-Cheng, et al.
Publicado: (2015)

A Meta-Analysis of the Efficacy of Interferon Monotherapy or Combined with Different Nucleos(t)ide Analogues for Chronic Hepatitis B
por: Zhou, Jialing, et al.
Publicado: (2016)

Response to: Comment on “48-Week Outcome after Cessation of Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Patient and the Associated Factors with Relapse”
por: Xu, Wen-xiong, et al.
Publicado: (2019)

Review of Laboratory Tests used in Monitoring Hepatitis B Response to Pegylated Interferon and Nucleos(t)ide Analog Therapy
por: Osiowy, Carla, et al.
Publicado: (2016)

Current Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B
por: Kim, Soon Sun, et al.
Publicado: (2011)

Effect of switching from treatment with nucleos(t)ide analogs to pegylated interferon α-2a on virological and serological responses in chronic hepatitis B patients
por: He, Li-Ting, et al.
Publicado: (2016)

Management of chronic hepatitis B patients: Efficacy & limitation of nucleos(t)ide analogues
por: Inoue, Jun, et al.
Publicado: (2011)

The impact of newer nucleos(t)ide analogues on patients with hepatitis B decompensated cirrhosis
por: Cholongitas, Evangelos, et al.
Publicado: (2015)

Is it possible to stop nucleos(t)ide analogue treatment in chronic hepatitis B patients?
por: Moreno-Cubero, Elia, et al.
Publicado: (2018)

Distinct histological patterns in chronic hepatitis D with nucleos(t)ide analogue therapy
por: Hercun, Julian, et al.
Publicado: (2023)

Kushenin Combined with Nucleos(t)ide Analogues for Chronic Hepatitis B: A Systematic Review and Meta-Analysis
por: Chen, Zhe, et al.
Publicado: (2015)

Pros and Cons of Peginterferon Versus Nucleos(t)ide Analogues for Treatment of Chronic Hepatitis B
por: Sonneveld, Milan J., et al.
Publicado: (2010)

Nucleos(t)ide analogues treatment outcome in genotype B and C chronic hepatitis B
por: Aung, Myo Nyein, et al.
Publicado: (2010)

Adverse events of nucleos(t)ide analogues for chronic hepatitis B: a systematic review
por: de Fraga, Raquel Scherer, et al.
Publicado: (2020)

Long-term efficacy and safety of nucleos(t)ides analogues in patients with chronic hepatitis B
por: Roade, Luisa, et al.
Publicado: (2021)

Arthrospira Enhances Seroclearance in Patients with Chronic Hepatitis B Receiving Nucleos(t)ide Analogue through Modulation of TNF-α/IFN-γ Profile
por: Shiue, Sheng-Jie, et al.
Publicado: (2022)

Comparison of the Efficacy of Entecavir and Tenofovir in Nucleos(T)ide Analogue-Experienced Chronic Hepatitis B Patients
por: Cho, Eun Ju, et al.
Publicado: (2015)

Emerging Diagnostic Tools to Decide When to Discontinue Nucleos(t)ide Analogues in Chronic Hepatitis B
por: Papatheodoridi, Margarita, et al.
Publicado: (2020)

Nucleos(t)ide analogues and Hepatitis B virus-related hepatocellular carcinoma: A literature review
por: Abd El Aziz, Mohamed A, et al.
Publicado: (2020)

Current Perspectives on Nucleos(t)ide Analogue Therapy for the Long-Term Treatment of Hepatitis B Virus
por: Broquetas, Teresa, et al.
Publicado: (2022)

TDF Monotherapy Is Effective Regardless of Prior Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Patients in China
por: Huang, Mingxing, et al.
Publicado: (2017)

Early Serum HBsAg Drop Is a Strong Predictor of HBeAg Seroconversion and HBsAg Loss to Pegylated Interferon Alfa-2a in Chronic Hepatitis B Patients with Prior Nucleos(t)ide Analogue Exposure
por: Chen, Qing, et al.
Publicado: (2019)

Tenofovir disoproxil fumarate for multiple nucleos(t)ide analogues treatment failure hepatitis B: Is monotherapy enough?
por: Liang, Xieer, et al.
Publicado: (2022)

Impact of Nucleos(t)ide Analogue Combination Therapy on the Estimated Glomerular Filtration Rate in Patients With Chronic Hepatitis B
por: Qi, Xun, et al.
Publicado: (2015)

Real-world study on clinical outcomes of nucleos(t)ide analogues antiviral therapy in patients with chronic hepatitis B
por: Sun, Y., et al.
Publicado: (2019)

Secondary prevention for hepatocellular carcinoma in patients with chronic hepatitis B: are all the nucleos(t)ide analogues the same?
por: Yip, Terry Cheuk-Fung, et al.
Publicado: (2020)

Detectable HBV DNA during nucleos(t)ide analogues stratifies predictive hepatocellular carcinoma risk score
por: Kaneko, Shun, et al.
Publicado: (2020)

Poor clinical and virological outcome of nucleos(t)ide analogue monotherapy in HBV/HDV co-infected patients
por: Scheller, Laura, et al.
Publicado: (2021)

Are nucleos(t)ide analogues effective against severe outcomes in COVID-19 and hepatitis B virus coinfection?
por: Adali, Gupse, et al.
Publicado: (2021)

Safety considerations for withdrawal of nucleos(t)ide analogues in patients with chronic hepatitis B: First, do no harm
por: Hsu, Yao-Chun, et al.
Publicado: (2023)

Systematic review with network meta-analysis: Comparative efficacy of oral nucleos(t)ide analogues for the prevention of chemotherapy-induced hepatitis B virus reactivation
por: Zhang, Min-Yue, et al.
Publicado: (2016)

On-treatment quantitative hepatitis B e antigen predicted response to nucleos(t)ide analogues in chronic hepatitis B
por: Gao, Yu-Hua, et al.
Publicado: (2016)

Potential resistant mutations within HBV reverse transcriptase sequences in nucleos(t)ide analogues-experienced patients with hepatitis B virus infection
por: Zhang, Xiaoman, et al.
Publicado: (2019)

Effect of nucleos(t)ide analogues on blood lipid profiles in patients with chronic hepatitis B: A cross-sectional survey
por: Chen, Jing Wen, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_a9mk0hibar7cg3bo8111id1fij